[1] Balgobind, B. V., Zwaan, C. M., Pieters, R., & Van den Heuvel-Eibrink, M. M. (2011). The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia, 25(8), 1239-1248.
[2] Berger, S. L., Kouzarides, T., Shiekhattar, R., &Shilatifard, A. (2009). An operational definition of epigenetics. Genes & development, 23(7), 781-783.
[3] Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., ... & Wells, C. E. (2010). Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer cell, 18(5), 436-447.
[4] Bots, M., &Johnstone, R. W. (2009). Rational combinations using HDAC inhibitors. Clinical cancer research, 15(12), 3970-3977.
[5] Cang, S., Ma, Y., & Liu, D. (2009). New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. Journal of hematology & oncology, 2(1), 22.
[6] Chase, A., & Cross, N. C. (2011). Aberrations of EZH2 in cancer. Clinical Cancer Research, 17(9), 2613-2618.
[7] Conerly, M., & Grady, W. M. (2010). Insights into the role of DNA methylation in disease through the use of mouse models. Disease models & mechanisms, 3(5-6), 290-297.
[8] Dawson, M. A., &Kouzarides, T. (2012). Cancer epigenetics: from mechanism to therapy. Cell, 150(1), 12-27.
[9] EinavNili, G. Y., Saito, Y., Egger, G., & Jones, P. A. (2008). Cancer epigenetics: modifications, screening, and therapy. Annu. Rev. Med., 59, 267-280.
[10] Esteller, M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Reviews Genetics, 8(4), 286-298.
[11] Esteller, M. (2008). Epigenetics in cancer. New England Journal of Medicine, 358(11), 1148-59.
[12] Feinberg, A. P., Ohlsson, R., &Henikoff, S. (2006). The epigenetic progenitor origin of human cancer. Nature reviews genetics, 7(1), 21-33.
[13] Greer, E. L., & Shi, Y. (2012). Histone methylation: a dynamic mark in health, disease and inheritance. Nature Reviews Genetics, 13(5), 343-357.
[14] Gui, Y., Guo, G., Huang, Y., Hu, X., Tang, A., Gao, S., ... & He, M. (2011). Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature genetics, 43(9), 875-878.
[15] Hargreaves, D. C., & Crabtree, G. R. (2011). ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell research, 21(3), 396-420.
[16] Hayashita, Y., Osada, H., Tatematsu, Y., Yamada, H., Yanagisawa, K., Tomida, S., ... & Takahashi, T. (2005). A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer research, 65(21), 9628-9632.
[17] Hoque, M. O., Kim, M. S., Ostrow, K. L., Liu, J., Wisman, G. B. A., Park, H. L., ... &Schuuring, E. (2008). Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer research, 68(8), 2661-2670.
[18] Jones, P. A., &Baylin, S. B. (2007). The epigenomics of cancer. Cell, 128(4), 683-692.
[19] Jones, P. A., & Taylor, S. M. (1980). Cellular differentiation, cytidine analogs and DNA methylation. Cell, 20(1), 85-93.
[20] Kacem, S., &Feil, R. (2009). Chromatin mechanisms in genomic imprinting. Mammalian Genome, 20(9-10), 544-556.
[21] le Sage, C., Nagel, R., Egan, D. A., Schrier, M., Mesman, E., Mangiola, A., ... &Farace, M. G. (2007). Regulation of the p27Kip1 tumor suppressor by miRâ€221 and miRâ€222 promotes cancer cell proliferation. The EMBO journal, 26(15), 3699-3708.
[22] Lin, H., Wong, R. P., Martinka, M., & Li, G. (2009). Loss of SNF5 expression correlates with poor patient survival in melanoma. Clinical Cancer Research, 15(20), 6404-6411.
[23] Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001). Histone deacetylases and cancer: causes and therapies. Nature Reviews Cancer, 1(3), 194-202.
[24] McCabe, M. T., Brandes, J. C., &Vertino, P. M. (2009). Cancer DNA methylation: molecular mechanisms and clinical implications. Clinical Cancer Research, 15(12), 3927-3937.
[25] Minucci, S., &Pelicci, P. G. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews Cancer, 6(1), 38-51.
[26] Miremadi, A., Oestergaard, M. Z., Pharoah, P. D., & Caldas, C. (2007). Cancer genetics of epigenetic genes. Human molecular genetics, 16(R1), R28-R49.
[27] Peter, M. E. (2009). Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell cycle, 8(6), 843-852.
[28] Rotili, D., & Mai, A. (2011). Targeting histone demethylases: a new avenue for the fight against cancer. Genes & cancer, 2(6), 663-679.
[29] Sadeh, R., & Allis, C. D. (2011). Genome-wide “reâ€-modeling of nucleosome positions. Cell, 147(2), 263-266.
[30] Shankar, S., &Srivastava, R. K. (2008). Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. In Programmed Cell Death in Cancer Progression and Therapy (pp. 261-298). Springer Netherlands.
[31] Smith, K. T., & Workman, J. L. (2009). Histone deacetylase inhibitors: anticancer compounds. The international journal of biochemistry & cell biology, 41(1), 21-25.
[32] Strahl, B. D., & Allis, C. D. (2000). The language of covalent histone modifications. Nature, 403(6765), 41-45.
[33] Straussman, R., Nejman, D., Roberts, D., Steinfeld, I., Blum, B., Benvenisty, N., ... & Cedar, H. (2009). Developmental programming of CpG island methylation profiles in the human genome. Nature structural & molecular biology, 16(5), 564-571.
[34] Visone, R., Russo, L., Pallante, P., De Martino, I., Ferraro, A., Leone, V., ... & Fusco, A. (2007). MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocrine-related cancer, 14(3), 791-798.
[35] Wolff, E. M., Byun, H. M., Han, H. F., Sharma, S., Nichols, P. W., Siegmund, K. D., ... & Liang, G. (2010). Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet, 6(4), e1000917.
[36] Yang, X. J. (2004). The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic acids research, 32(3), 959-976.
[37] Yoo, C. B., & Jones, P. A. (2006). Epigenetic therapy of cancer: past, present and future. Nature reviews Drug discovery, 5(1), 37-50.